Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8(+) T cell activation in the presence of adjuvant temozolomide

In a two-stage phase II study, 24 patients with first diagnosis of glioblastoma (GBM) were treated with dendritic cell (DC) immunotherapy associated to standard radiochemotherapy with temozolomide (TMZ) followed by adjuvant TMZ. Three intradermal injections of mature DC loaded with autologous GBM ly...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Oncoimmunology
المؤلفون الرئيسيون: Pellegatta, Serena, Eoli, Marica, Cuccarini, Valeria, Anghileri, Elena, Pollo, Bianca, Pessina, Sara, Frigerio, Simona, Servida, Maura, Cuppini, Lucia, Antozzi, Carlo, Cuzzubbo, Stefania, Corbetta, Cristina, Paterra, Rosina, Acerbi, Francesco, Ferroli, Paolo, DiMeco, Francesco, Fariselli, Laura, Parati, Eugenio A., Bruzzone, Maria Grazia, Finocchiaro, Gaetano
التنسيق: Artigo
اللغة:Inglês
منشور في: Taylor & Francis 2018
الموضوعات:
Original Research
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889286/
https://ncbi.nlm.nih.gov/pubmed/29632727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1412901
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة